Helikon Investments Ltd Takes a New Position in Grifols, S.A. with $580,000 Investment

Helikon Investments Ltd has taken a new position in Grifols, S.A. (NASDAQ:GRFS). According to a recent filing with the Securities and Exchange Commission (SEC), the investment firm acquired 78,010 shares of the biotechnology company during the fourth quarter, which is valued at approximately $580,000. This new investment represents 0.1% of Helikon Investments Ltd's total portfolio, making Grifols its 19th largest holding.

• 3 Health Care Stocks That Could Double by Year End

Other hedge funds have also been active with Grifols stock, buying and selling shares. Notably, the Bank of Montreal Can increased its stake by 12.4% in the second quarter, now owning 70,640 shares worth $446,000 after purchasing an additional 7,786 shares. In addition, AQR Capital Management LLC initiated a new position in Grifols during the same period, investing $89,000. B. Riley Wealth Advisors Inc. also acquired a new stake valued at $359,000, while Brandes Investment Partners LP enhanced its holdings by 8.7% in the second quarter, now owning 18,596,790 shares, valued at $117,242,000 after obtaining an additional 1,481,924 shares. Moreover, Point72 Asset Management L.P. increased its investment in Grifols by 34.4%, bringing its total holding to 596,845 shares, worth $3,763,000 after acquiring 152,700 more shares last quarter.

Analyst Upgrades and Downgrades

In related news, Berenberg Bank upgraded Grifols to a "strong-buy" rating in a recent research note.

Check Out Our Latest Stock Analysis on GRFS

Grifols Shares Decline

The stock of Grifols opened at $7.35 on Monday, experiencing a decline of 1.6%. The company holds a debt-to-equity ratio of 1.11 and a current ratio of 2.26, with a quick ratio of 0.79. The fifty-day moving average price for the stock stands at $7.66, while the 200-day moving average price is $8.19. Over the past year, Grifols has seen a low of $5.30 and a high of $9.96.

About Grifols

Grifols, S.A. operates as a global leader in plasma therapeutics, offering a range of products across Spain, the United States, Canada, and other regions. The company's offerings include immunoglobulin for treating immunodeficiencies, albumin to restore circulatory volume during health crises, and treatments related to hemophilia and hereditary diseases.

Further Insights and Recommendations

• Five stocks we like better than Grifols
• The How and Why of Investing in Gold Stocks
• A Pivotal Moment for the Consumer Discretionary Sector
• Uptrend Stocks Explained: Learn How to Trade Using Uptrends
• How Mixed Analyst Opinions Are Shaping Apple Stock’s Outlook
• Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
• Why Rezolve Could Be the Next Big Name in Artificial Intelligence

Want to see what other hedge funds are holding GRFS? Be sure to check the latest 13F filings and insider trades for Grifols, S.A.

This report was prepared to provide the latest information on investment activities related to Grifols and was reviewed for accuracy.

Is Grifols a Good Investment Right Now?

Before deciding on an investment in Grifols, it's important to consider various expert opinions.

Market analysts have compiled a list of top-rated stocks that they believe are solid options right now, and currently, Grifols is not featured on this exclusive list. Though Grifols holds a "Moderate Buy" rating, experts indicate there are other stocks that might offer better investment opportunities.

Explore these top-rated stocks for potential investment insights.

investment, stocks, Grifols